Evidence map›Paper›PMID 37124027›Full record

ArticleAdvances in radiation oncology

Planning for the Effect of the SC.24 Trial on Spine Stereotactic Body Radiation Therapy Utilization at a Tertiary Cancer Center.

Andrew J Arifin, Sympascho Young, Glenn S Bauman, Hatim Fakir, Belal Ahmad, Joanna M Laba, George B Rodrigues, Eric K Nguyen, Arjun Sahgal, Timothy K Nguyen

Open access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Geranylgeranyl Transferase Inhibitors Mitigate Intestinal Radiation Toxicity.International journal of radiation oncology, biology, physics · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Andrew J ArifinDivision of Radiation Oncology, London Regional Cancer Program, London, Ontario, Canada.
Sympascho YoungDivision of Radiation Oncology, London Regional Cancer Program, London, Ontario, Canada.
Glenn S BaumanDivision of Radiation Oncology, London Regional Cancer Program, London, Ontario, Canada.
Hatim FakirDivision of Radiation Oncology, London Regional Cancer Program, London, Ontario, Canada.
Belal AhmadDivision of Radiation Oncology, London Regional Cancer Program, London, Ontario, Canada.
Joanna M LabaDivision of Radiation Oncology, London Regional Cancer Program, London, Ontario, Canada.
George B RodriguesDivision of Radiation Oncology, London Regional Cancer Program, London, Ontario, Canada.
Eric K NguyenDepartment of Radiation Oncology, Walker Family Cancer Centre, St. Catharines, Ontario, Canada.
Arjun SahgalDepartment of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Timothy K NguyenDivision of Radiation Oncology, London Regional Cancer Program, London, Ontario, Canada.
Cancer Care Ontario · CASunnybrook Health Science Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The goal of this study was to assess the potential real-world effect of the recently reported SC.24 trial on spine stereotactic body radiation therapy (SBRT) utilization. We estimated the proportion of patients treated with conventional radiation therapy (CRT) who would have been eligible for spine SBRT per trial inclusion criteria and analyzed the potential estimated increased costs to our institution. Methods and Materials: This was a retrospective review of patients who received spine CRT at our institution between August and October 2020. Data abstracted included demographics, SC.24 eligibility criteria, provider-reported pain response, and survival. A cost analysis and time survey was performed using institutional and provincial data. Results: Of 73 patients reviewed, 24 patients (33%) were eligible. The most common exclusion factors included irradiation of ≥3 consecutive spinal segments (n = 32, 44%), Eastern Cooperative Oncology Group performance status >2 (n = 17, 23%), and symptomatic spinal cord compression (n = 13, 18%). Of eligible patients, the mean age was 68.92 years, median spinal instability in neoplasia score was 8 (interquartile range, 7-9), and median Eastern Cooperative Oncology Group performance status was 2 (interquartile range, 1-2). The most common primary cancer types among eligible patients were lung (n = 10) and breast (n = 4). The median survival of eligible patients was 10 months (95% confidence interval, 4 months to not reached) with 58% surviving longer than 3 months. Of patients who had subjective pain documented after CRT, 54% had at least some response. The cost of spine SBRT was estimated at CA$4764.80 compared with $3589.10 for CRT, and tasks for spine SBRT took roughly 3 times as long as those for CRT. Conclusions: One-third of patients who received palliative spine CRT met eligibility criteria for SC.24. This possible expanded indication for spine SBRT can have a substantial effect on resource utilization. These data may be useful in guiding resource planning at institutions looking to commence a spine SBRT program.

Identifiers

PMID37124027
PMCPMC10130065
OpenAlexW4327748754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.